Lastly, the mRNA-5671 cancer vaccine for KRAS G12C, G12D, G13D and G12V is currently being tested in a phase I study as a monotherapy as well as with the PD1 inhibitor pembrolizumab in advanced or metastatic KRAS mutant NSCLC, colorectal and pancreatic cancer patients with an estimated study completion date being end of 2026 (Clinicaltrials.gov Identifier: NCT03948763 (accessed on 24 February 2021)) [4]. The gene discussed is KRAS; the disease is cancer.